Abstract

BackgroundStudies on the inhibition of inflammation by infection with helminth parasites have, until recently, overlooked a key determinant of health: the gut microbiota. Infection with helminths evokes changes in the composition of their host’s microbiota: one outcome of which is an altered metabolome (e.g., levels of short-chain fatty acids (SCFAs)) in the gut lumen. The functional implications of helminth-evoked changes in the enteric microbiome (composition and metabolites) are poorly understood and are explored with respect to controlling enteric inflammation.MethodsAntibiotic-treated wild-type, germ-free (GF) and free fatty-acid receptor-2 (ffar2) deficient mice were infected with the tapeworm Hymenolepis diminuta, then challenged with DNBS-colitis and disease severity and gut expression of the il-10 receptor-α and SCFA receptors/transporters assessed 3 days later. Gut bacteria composition was assessed by 16 s rRNA sequencing and SCFAs were measured. Other studies assessed the ability of feces or a bacteria-free fecal filtrate from H. diminuta-infected mice to inhibit colitis.ResultsProtection against disease by infection with H. diminuta was abrogated by antibiotic treatment and was not observed in GF-mice. Bacterial community profiling revealed an increase in variants belonging to the families Lachnospiraceae and Clostridium cluster XIVa in mice 8 days post-infection with H. diminuta, and the transfer of feces from these mice suppressed DNBS-colitis in GF-mice. Mice treated with a bacteria-free filtrate of feces from H. diminuta-infected mice were protected from DNBS-colitis. Metabolomic analysis revealed increased acetate and butyrate (both or which can reduce colitis) in feces from H. diminuta-infected mice, but not from antibiotic-treated H. diminuta-infected mice. H. diminuta-induced protection against DNBS-colitis was not observed in ffar2−/− mice. Immunologically, anti-il-10 antibodies inhibited the anti-colitic effect of H. diminuta-infection. Analyses of epithelial cell lines, colonoids, and colon segments uncovered reciprocity between butyrate and il-10 in the induction of the il-10-receptor and butyrate transporters.ConclusionHaving defined a feed-forward signaling loop between il-10 and butyrate following infection with H. diminuta, this study identifies the gut microbiome as a critical component of the anti-colitic effect of this helminth therapy. We suggest that any intention-to-treat with helminth therapy should be based on the characterization of the patient’s immunological and microbiological response to the helminth.

Highlights

  • Despite significant increases in therapeutics for chronic inflammatory disease, even the best of these is ineffective in a substantial number of patients

  • Differential abundance analysis revealed significant increases in amplicon sequence variant (ASV) in the family Lachnospiraceae (p=2.92 × 10-14) and the Clostridium clusters XIVa (p = 1.24 × 10−4) and XIVb (p=1.94 × 10−16) in H. diminuta+dinitrobenzene sulphonic acid (DNBS) treated mice compared to DNBS-only treatment (Fig. 2C)

  • Mice treated with ABX displayed severe disruption of their microbiota (Fig. 2A, D–F), with a general shift away from Firmicutes and to Bacteroidetes (Fig. 2F)

Read more

Summary

Introduction

Despite significant increases in therapeutics for chronic inflammatory disease, even the best of these (e.g., antiTNFα antibody) is ineffective in a substantial number of patients. Analyses of animal models show that infection with helminth parasites reduces the severity of inflammatory disease [6,7,8,9,10,11], in which interleukin (il), transforming growth factor (tgf)-β, and regulatory T cells, B cells, and macrophages were critical host factors in the inhibition of inflammation [12,13,14,15,16] This immune-centric view of the host-parasite interaction overlooks the possible, if not probable, participation of the microbiome in a tripartite relationship. The functional implications of helminth-evoked changes in the enteric microbiome (composition and metabolites) are poorly understood and are explored with respect to controlling enteric inflammation

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call